PRODUCT INFORMATION

CCG-100602

Item No. 10787

CAS Registry No.:	1207113-88-9
Formal Name:	1-[3,5-*bis*(trifluoromethyl) benzoyl]-N-(4-chlorophenyl)-3-piperidinecarboxamide
MF:	$C_{21}H_{17}ClF_6N_2O_2$
FW:	478.8
Purity:	≥98%
UV/Vis.:	λ_{max}: 250 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CCG-100602 is supplied as a crystalline solid. A stock solution may be made by dissolving the CCG-100602 in the solvent of choice, which should be purged with an inert gas. CCG-100602 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of CCG-100602 in ethanol is approximately 0.2 mg/ml and approximately 20 mg/ml in DMSO and DMF.

Description

The Rho family of small GTPases play an important role in transduction of cell signaling events associated with several human cancers. CCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. The site of inhibition in the pathway is not precisely defined but CCG-1423 appears to act on some aspect of the interaction of SRF with its transcriptional cofactor megakaryoblastic leukemia 1 (MKL1) at a point upstream of DNA binding.[1] CCG-100602 is a CCG-1423 analog developed for improved selectivity, potency, and attenuated cytotoxicity relative to its parent compound. CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells with an IC_{50} value of 9.8 µM. At 100 µM, CCG-100602 demonstrates 72% inhibition of PC-3 cell invasion into a Matrigel model of metastasis, exhibiting an efficacy:toxicity profile superior to that of CCG-1423 at 10 µM.[2]

References

1. Evelyn, C.R., Wade, S.M., Wang, Q., *et al.* CCG-1423: A small-molecule inhibitor of RhoA transcriptional signaling. *Mol. Cancer Ther.* **6(8)**, 2249-2260 (2007).
2. Evelyn, C.R., Bell, J.L., Ryu, J.G., *et al.* Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. *Bioorg. Med. Chem. Lett.* **20(2)**, 665-672 (2010).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM